32 /100
MEDIUM RISK
Score updated Jun 11, 2026

VLN — Valens Semiconductor Ltd. Dilution Risk Tracker

Track VLN dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track VLN — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
25
📊 Float Risk
20
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

Watch
Minor dilution signals detected
15%
🔄 Reverse Split 30%
• 50-day avg $1.99 approaching $1 threshold
🔔 Track VLN — Get forecast alerts →

💹 Market Data

Market Cap$373.20M
Shares Outstanding103.05M
Float74.03M
Cash$92.60M
Debt$6.39M
Short InterestN/A

🏛 Institutional Holdings

10 institutional holders · 32.45M shares
#1 Value Base Ltd. 21.48M shares
#2 Clal Insurance Enterprises Holdings Ltd 1.98M shares
#3 Marshall Wace LLP 1.83M shares
+ 7 more holders Sign up free to view →

📉 Short Interest

Short Interest1.67M
Days to Cover1.0
% of Float2.2%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2023
xbrl XBRL CONVERTIBLE Dec 31, 2021
Form 4 INSIDER TRANSACTION May 13, 2026
Form 4 INSIDER TRANSACTION May 13, 2026
Form 4 INSIDER TRANSACTION May 08, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track VLN Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking VLN — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

🔬 More Research for VLN
📊 VLN FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 VLN Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.